Niagen Bioscience, Inc. (NAGE) Stock Forecast
NAGE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 6 analysts
- Price target
- $12.08 average of analyst targets
- Upside to target
- +385.3% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.00
- 52-week range
- $2.49 – $7.60
NAGE analyst ratings
6 analystsNumber of analysts at each rating.
NAGE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NAGE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.03 | −$0.03 | $0.05 | −160.0% | 1 |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | $0.17 | −100.0% | 1 |
| Next fiscal year (2027) | −$0.06 | −$0.06 | −$0.06 | $0.00 | 0.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NAGE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $34.3M | $33.0M | $35.9M | +0.8% | 4 |
| Current fiscal year (2026) | $133.2M | $130.3M | $134.9M | +2.9% | 4 |
| Next fiscal year (2027) | $154.7M | $153.0M | $156.5M | +16.2% | 4 |
NAGE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NAGE revenue: reported and forecast
NAGE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.03 | −$0.01 | −$0.01 | −$0.01 | −$0.03 | −200.0% | 0 up · 1 down |
| Current fiscal year (2026) | $0.19 | $0.09 | $0.09 | $0.09 | $0.00 | −100.0% | 0 up · 1 down |
| Next fiscal year (2027) | $0.29 | $0.10 | $0.10 | $0.10 | −$0.06 | −120.7% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NAGE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NAGE beat in 11 of 12.
What analysts expect from NAGE
6 analysts cover Niagen Bioscience; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.08, 385.3% above the latest close of $2.49. Analysts expect earnings of $0.00 per share for 2026, −100.0% from a year earlier. For 2027 the average estimate is −$0.06 per share on revenue of $154.7 million. Niagen Bioscience beat the EPS estimate in 11 of the last 12 quarters.
Related: NAGE income statement, NAGE key metrics, NAGE chart. See the NAGE stock overview for the latest quote and news.
NAGE forecast FAQ
What is Niagen Bioscience's price target?
The average analyst price target for Niagen Bioscience is $12.08, 385.3% above the latest close of $2.49.
Is Niagen Bioscience a buy, hold or sell?
Of 6 analysts covering Niagen Bioscience, 6 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Niagen Bioscience's EPS forecast?
Analysts forecast $0.00 per share for 2026 (range $0.00 to $0.00); for 2027 the estimate is −$0.06.
What is Niagen Bioscience's revenue forecast?
The average revenue estimate for 2026 is $133.2 million, growth of 2.9%; for 2027 it is $154.7 million.
When does Niagen Bioscience report earnings?
Niagen Bioscience is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $0.00.
Does Niagen Bioscience usually beat earnings estimates?
Niagen Bioscience reported EPS at or above the analyst estimate in 11 of the last 12 quarters.